In conclusion, the extended GLISCAR study suggests that SGLT2 inhibitors may exert favorable effects on both left ventricular and RV function, and on pulmonary hemodynamics, in patients with HFrEF and T2D. Here, SLC5A2 is linked to type 2 diabetes mellitus.